{"analyses":[{"ciLowerLimit":"1.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.55","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"The Hazard Ratio and 95% confidence intervals were based on Cox regression model with treatment as a covariate stratified by disease status (refractory vs. sensitive to Lenalidomide) and Lines of previous treatments (two vs. three or more).","pValue":"0.99989","paramType":"Hazard Ratio (HR)","paramValue":"1.84","statisticalComment":"One-sided p-value based on Stratified log-rank test.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.2","upperLimit":"29.1","value":"21.0"},{"comment":"OS upper limit was not reached due to an insufficient number of deaths.","groupId":"OG001","lowerLimit":"28.5","upperLimit":"NA","value":"39.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Median overall survival was calculated from the product-limit (Kaplan-Meier) method for censored data. The database cutoff date was August 3, 2020.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"Pembrolizumab+Pomalidomide+Dexamethasone"},{"description":"Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG001","title":"Standard of Care (SOC) Pomalidomide+Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all randomized participants. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 54 months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}